View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2014	Oct. 24, 2014
Document and Entity Information
Entity Registrant Name	Alkermes plc.
Entity Central Index Key	0001520262
Document Type	10-Q
Document Period End Date	Sep. 30, 2014
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		146,231,502
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2014	Dec. 31, 2013
CURRENT ASSETS:
Cash and cash equivalents	$ 136,182	$ 167,562
Investments - short-term	436,387	194,669
Receivables	143,692	134,154
Inventory	50,471	46,218
Prepaid expenses and other current assets	46,174	27,535
Total current assets	812,906	570,138
PROPERTY, PLANT AND EQUIPMENT, NET	262,128	274,490
INTANGIBLE ASSETS - NET	494,656	537,565
GOODWILL	92,740	92,740
INVESTMENTS - LONG-TERM	143,747	87,764
OTHER ASSETS	31,678	14,891
TOTAL ASSETS	1,837,855	1,577,588
CURRENT LIABILITIES:
Accounts payable and accrued expenses	100,329	91,173
Long-term debt - current	6,750	6,750
Deferred revenue - current	3,061	2,974
Total current liabilities	110,140	100,897
LONG-TERM DEBT	352,801	357,543
DEFERRED TAX LIABILITIES, NET - LONG-TERM	21,258	29,169
DEFERRED REVENUE - LONG-TERM	11,519	12,213
OTHER LONG-TERM LIABILITIES	8,545	12,580
Total liabilities	504,263	512,402
COMMITMENTS AND CONTINGENCIES (Note 16)
SHAREHOLDERS' EQUITY:
Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; zero issued and outstanding at September 30, 2014 and December 31, 2013, respectively
Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 147,071,192 and 138,482,571 shares issued; 146,088,467 and 137,792,626 shares outstanding at September 30, 2014 and December 31, 2013, respectively	1,468	1,382
Treasury shares, at cost (982,725 and 689,945 shares at September 30, 2014 and December 31, 2013, respectively)	(30,881)	(17,833)
Additional paid-in capital	1,908,721	1,553,337
Accumulated other comprehensive (loss) income	(2,866)	10,574
Accumulated deficit	(542,850)	(482,274)
Total shareholders' equity	1,333,592	1,065,186
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 1,837,855	$ 1,577,588

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2014	Dec. 31, 2013
CONDENSED CONSOLIDATED BALANCE SHEETS
Preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred shares, authorized	50,000,000	50,000,000
Preferred shares, issued	0	0
Preferred shares, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	450,000,000	450,000,000
Common stock, shares issued	147,071,192	138,482,571
Common stock, shares outstanding	146,088,467	137,792,626
Treasury share	982,725	689,945

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
REVENUES:
Manufacturing and royalty revenues	$ 132,028	$ 118,571	$ 373,674	$ 385,278
Product sales, net	25,802	19,227	64,476	51,232
Research and development revenue	2,162	2,004	5,478	5,345
Total revenues	159,992	139,802	443,628	441,855
EXPENSES:
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)	47,335	45,423	129,464	139,407
Research and development	78,263	45,947	197,610	115,209
Selling, general and administrative	51,888	39,454	145,101	107,066
Amortization of acquired intangible assets	15,244	12,856	42,909	35,894
Restructuring				12,300
Impairment of long-lived assets				3,346
Total expenses	192,730	143,680	515,084	413,222
OPERATING (LOSS) INCOME	(32,738)	(3,878)	(71,456)	28,633
OTHER (EXPENSE) INCOME, NET:
Interest income	546	295	1,380	627
Interest expense	(3,356)	(3,477)	(10,097)	(18,418)
Gain on sale of investment in Acceleron Pharma Inc.			15,296
Gain on sale of property, plant and equipment	36		12,321
Other (expense) income, net	(921)	(469)	(2,253)	(455)
Total other (expense) income, net	(3,695)	(3,651)	16,647	(18,246)
(LOSS) INCOME BEFORE INCOME TAXES	(36,433)	(7,529)	(54,809)	10,387
INCOME TAX PROVISION	3,523	233	5,766	7,818
NET (LOSS) INCOME	$ (39,956)	$ (7,762)	$ (60,575)	$ 2,569
(LOSS) EARNINGS PER ORDINARY SHARE:
Basic (in dollars per share)	$ (0.27)	$ (0.06)	$ (0.42)	$ 0.02
Diluted (in dollars per share)	$ (0.27)	$ (0.06)	$ (0.42)	$ 0.02
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING:
Basic (in shares)	145,896	136,106	144,732	134,670
Diluted (in shares)	145,896	136,106	144,732	143,022
COMPREHENSIVE (LOSS) INCOME:
Net (loss) income	$ (39,956)	$ (7,762)	$ (60,575)	$ 2,569
Holding (losses) gains, net of tax of $89, none, $7,715 and none, respectively	(154)	8,506	1,855	8,241
Reclassification of unrealized gains to realized gains			(15,296)
COMPREHENSIVE (LOSS) INCOME	$ (40,110)	$ 744	$ (74,016)	$ 10,810

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME
Holding (losses), tax	$ 89	$ 0	$ 7,715	$ 0

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$ (60,575)	$ 2,569
Adjustments to reconcile net (loss) income to cash flows from operating activities:
Depreciation and amortization	72,719	65,722
Share-based compensation expense	46,240	30,899
Excess tax benefit from share-based compensation	(22,444)	(12,969)
Impairment of long-lived assets		3,346
(Gain) loss on sale of property, plant and equipment	(11,942)	391
Gain on sale of investment of Acceleron Pharma Inc.	(15,296)
Deferred income taxes	(18,731)	(2,049)
Loss on debt refinancing transaction		7,541
Prepayment penalty in connection with debt refinancing		(3,733)
Other non-cash charges	9,921	2,177
Changes in assets and liabilities:
Receivables	(9,538)	(613)
Inventory, prepaid expenses and other assets	(17,774)	(2,530)
Accounts payable and accrued expenses	25,103	18,869
Deferred revenue	(607)	(208)
Other long-term liabilities	420	7
Cash flows (used in) provided by operating activities	(2,504)	109,419
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions of property, plant and equipment	(20,326)	(17,457)
Proceeds from the sale of property, plant and equipment	14,361	125
Investment in Civitas Therapeutics, Inc.		(1,191)
Purchases of investments	(550,102)	(196,525)
Sales and maturities of investments	246,540	95,149
Cash flows used in investing activities	(309,527)	(119,899)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issuance of ordinary shares, net	248,406
Proceeds from the issuance of ordinary shares under share-based compensation arrangements	27,431	50,790
Excess tax benefit from share-based compensation	22,444	12,969
Employee taxes paid related to net share settlement of equity awards	(12,566)	(8,529)
Principal payments of long-term debt	(5,064)	(7,137)
Cash flows provided by financing activities	280,651	48,093
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(31,380)	37,613
CASH AND CASH EQUIVALENTS - Beginning of period	167,562	135,892
CASH AND CASH EQUIVALENTS - End of period	136,182	173,505
Non-cash investing and financing activities:
Purchased capital expenditures included in accounts payable and accrued expenses	$ 691	$ 1,184

THE COMPANY	9 Months Ended
THE COMPANY	Sep. 30, 2014
THE COMPANY
THE COMPANY	1. THE COMPANY Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. Alkermes has a diversified portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address CNS disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes has a research and development (“R&D”) center in Waltham, Massachusetts; R&D and manufacturing facilities in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia and Wilmington, Ohio.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying condensed consolidated financial statements of the Company for the three and nine months ended September 30, 2014 and 2013 are unaudited and have been prepared on a basis substantially consistent with the audited financial statements for the nine-month transition period ended December 31, 2013 (the “Transition Period”). The year-end Condensed Consolidated Balance Sheet data, which is presented for comparative purposes, was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (“U.S.”) (commonly referred to as “GAAP”). In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, that are necessary to present fairly the results of operations for the reported periods. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto of Alkermes, which are contained in the Company’s Transition Report on Form 10-KT, which has been filed with the SEC. The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period, including the Transition Period, or for a full fiscal year. Principles of Consolidation The condensed consolidated financial statements include the accounts of Alkermes plc and its wholly owned subsidiaries as disclosed in Note 2: Summary of Significant Accounting Policies within Part II, Item 8 of our Transition Report. During the nine months ended September 30, 2014, the following wholly owned subsidiaries were added:Alkermes Science Three Limited; Alkermes Science Four Limited; Alkermes Science Five Limited; and Alkermes Science Six Limited. Intercompany accounts and transactions have been eliminated. Use of Estimates The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates and judgments and methodologies, including those related to revenue recognition and related allowances, its collaborative relationships, clinical trial expenses, the valuation of inventory, impairment and amortization of intangibles and long-lived assets, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of investments and derivative instruments, litigation and restructuring charges. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Segment Information The Company operates as one business segment, which is the business of developing, manufacturing and commercializing medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious diseases. The Company’s chief decision maker, the Chairman and Chief Executive Officer, reviews the Company’s operating results on an aggregate basis and manages the Company’s operations as a single operating unit. New Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard-setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. In July 2013, the FASB adopted clarifying guidance on the presentation of unrecognized tax benefits when various qualifying tax credits exist. The amendment requires that unrecognized tax benefits be presented on the consolidated balance sheet as a reduction to deferred tax assets created by net operating losses (‘‘NOLs’’) or other tax credits from prior periods that occur in the same taxing jurisdiction. To the extent that the unrecognized tax benefit exceeds these NOLs or other tax credits, it shall be presented as a liability. This update, required to be adopted for all annual periods and interim reporting periods beginning after December 15, 2013, was adopted by the Company on January 1, 2014. The adoption of this standard did not have a material impact on the presentation of the Company’s financial position. In April 2014, the FASB adopted guidance that amends the requirements for reporting discontinued operations. Under the amendment, only those disposals of components of an entity that represent a strategic shift that has (or will have) a major effect on an entity's operations and financial results will be reported as discontinued operations in the financial statements. Currently, many disposals, some of which may be routine in nature and not a change in an entity's strategy, are reported in discontinued operations. The guidance also requires expanded disclosures for discontinued operations. This guidance becomes effective for the Company in its year ending December 31, 2015 and early adoption is permitted, but only for disposals that have not been reported in financial statements previously issued or available for issuance. The adoption of this standard is not expected to have a material impact on the Company's results of operations, cash flows or financial condition. In June 2014, the FASB issued guidance that clarifies the accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period. Existing GAAP does not contain explicit guidance on how to account for these share-based payments. The new guidance requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. Entities have the option of prospectively applying the guidance to awards granted or modified after the effective date or retrospectively applying the guidance to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements. The guidance becomes effective for the Company in its year ending December 31, 2016, and early adoption is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In May 2014, the FASB issued guidance that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. The guidance becomes effective for the Company in its year ending December 31, 2017, and early adoption is not permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

INVESTMENTS

9 Months Ended

Sep. 30, 2014

INVESTMENTS

INVESTMENTS

3. INVESTMENTS

Investments consisted of the following:

			Gross Unrealized
					Losses
	Amortized				Less than			Greater than			Estimated
	Cost		Gains		One Year			One Year			Fair Value
	(In thousands)
September 30, 2014
Short-term investments:
Available-for-sale securities:
U.S. government and agency debt securities	$	220,312	$	170	$	—		$	—		$	220,482
Corporate debt securities	178,312		97		(46		)	—			178,363
International government agency debt securities	36,321		20		—			—			36,341
	434,945		287		(46		)	—			435,186
Money market funds	1,201		—		—			—			1,201
Total short-term investments	436,146		287		(46		)	—			436,387
Long-term investments:
Available-for-sale securities:
U.S. government and agency debt securities	101,464		—		(163		)	(22		)	101,279
Corporate debt securities	31,390		—		(37		)	(4		)	31,349
International government agency debt securities	9,577		—		(4		)	(1		)	9,572
	142,431		—		(204		)	(27		)	142,200
Held-to-maturity securities:
Certificates of deposit	1,547		—		—			—			1,547
Total long-term investments	143,978		—		(204		)	(27		)	143,747
Total investments	$	580,124	$	287	$	(250	)	$	(27	)	$	580,134

December 31, 2013
Short-term investments:
Available-for-sale securities:
U.S. government and agency debt securities	$	130,669	$	80	$	(1	)	$	—		$	130,748
Corporate debt securities	38,614		64		(30		)	—			38,648
International government agency debt securities	24,097		8		(33		)	—			24,072
	193,380		152		(64		)	—			193,468
Money market funds	1,201		—		—			—			1,201
Total short-term investments	194,581		152		(64		)	—			194,669
Long-term investments:
Available-for-sale securities:
Equity securities	8,732		21,253		—			—			29,985
U.S. government and agency debt securities	28,503		—		(61		)	(3		)	28,439
Corporate debt securities	20,266		—		(30		)	(75		)	20,161
International government agency debt securities	7,691		—		(5		)	—			7,686
	65,192		21,253		(96		)	(78		)	86,271
Held-to-maturity securities:
Certificates of deposit	1,493		—		—			—			1,493
Total long-term investments	66,685		21,253		(96		)	(78		)	87,764
Total investments	$	261,266	$	21,405	$	(160	)	$	(78	)	$	282,433

The proceeds from the sales and maturities of marketable securities, which were primarily reinvested and resulted in realized gains and losses, were as follows:

	Nine Months Ended
	September 30,
(In thousands)	2014			2013
Proceeds from the sales and maturities of marketable securities	$	246,540		$	95,149
Realized gains	$	15,352		$	54
Realized losses	$	(10	)	$	(5	)

During the three months ended June 30, 2014, the Company sold its investment in Acceleron Pharma Inc. (“Acceleron”), which consisted of common stock and warrants to purchase the common stock of Acceleron. The Company received net proceeds of $24.0 million and realized a gain of $15.3 million from the sale of this investment. The Company reclassified the gain from accumulated other comprehensive (loss) income to gain on sale of investment in Acceleron in its Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income.

The Company’s available-for-sale and held-to-maturity securities at September 30, 2014 had contractual maturities in the following periods:

	Available-for-sale				Held-to-maturity
	Amortized		Estimated		Amortized		Estimated
(In thousands)	Cost		Fair Value		Cost		Fair Value
Within 1 year	$	298,878	$	298,972	$	1,547	$	1,547
After 1 year through 5 years	278,498		278,414		—		—
Total	$	577,376	$	577,386	$	1,547	$	1,547

At September 30, 2014, the Company believed that the unrealized losses on its available-for-sale investments were temporary. The investments with unrealized losses consisted primarily of U.S. government and agency debt securities and corporate debt securities. In making the determination that the decline in fair value of these securities was temporary, the Company considered various factors, including but not limited to: the length of time each security was in an unrealized loss position; the extent to which fair value was less than cost; financial condition and near-term prospects of the issuers; and the Company’s intent not to sell these securities and the assessment that it is more likely than not that the Company would not be required to sell these securities before the recovery of their amortized cost basis.

The Company’s investment in Civitas Therapeutics, Inc. (“Civitas”) was zero and $2.0 million at September 30, 2014 and December 31, 2013, respectively, which was recorded within “Other Assets” in the accompanying Condensed Consolidated Balance Sheets. During the nine months ended September 30, 2014, the Company invested an additional $1.0 million in Civitas and recorded a reduction in its investment in Civitas of $2.0 million, which represented the Company’s proportionate share of Civitas’ net losses for this period. As the Company’s interest in Civitas has reached zero, the Company no longer records its proportionate share of Civitas’ net losses until such time as the Company’s share of Civitas’ net income exceeds its share of Civitas’ net losses not recognized during the period the equity method is suspended.

In October 2014, Civitas was acquired by Acorda Therapeutics, Inc. (“Acorda”) for approximately $525.0 million. As a result of this transaction, the Company received $30.0 million for the sale of certain commercial-scale pulmonary manufacturing equipment used by Civitas. The Company also received $27.2 million and will receive an additional $2.3 million, subject to release of all amounts held in escrow, for its approximate 6% equity interest in Civitas.

In May 2014, the Company entered into an agreement whereby it is committed to provide up to €7.4 million to a partnership, Fountain Healthcare Partners II, L.P. of Ireland (“Fountain”), which was created to carry on the business of investing exclusively in companies and businesses engaged in healthcare, pharmaceutical and life sciences sectors. The Company’s commitment represents approximately 10% of the partnership’s total funding, and the Company is accounting for its investment in Fountain under the equity method. At September 30, 2014, the Company had made payments of, and its investment is equal to, $1.2 million (€0.9 million), which is included within “Other assets” in the accompanying Condensed Consolidated Balance Sheets.

FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2014

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

4. FAIR VALUE MEASUREMENTS

The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:

	September 30,
(In thousands)	2014		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	1,201	$	1,201	$	—	$	—
U.S. government and agency debt securities	321,761		169,120		152,641		—
Corporate debt securities	209,712		—		209,712		—
International government agency debt securities	45,913		—		45,913		—
Total	$	578,587	$	170,321	$	408,266	$	—

	December 31,
	2013			Level 1		Level 2			Level 3
Assets:
Cash equivalents	$	1,201		$	1,201	$	—		$	—
U.S. government and agency debt securities	159,187			63,213		95,974			—
Corporate debt securities	58,809			—		58,809			—
International government agency debt securities	31,758			—		31,758			—
Equity securities	29,985			28,459		—			1,526
Total	$	280,940		$	92,873	$	186,541		$	1,526

Liabilities:
Interest rate swap contract	$	(275	)	$	—	$	(275	)	$	—
Total	$	(275	)	$	—	$	(275	)	$	—

The Company transfers its financial assets and liabilities, measured at fair value on a recurring basis, between the fair value hierarchies at the end of each reporting period.

There were no transfers of any securities from Level 1 to Level 2 or from Level 2 to Level 1 during the nine months ended September 30, 2014. The following table is a rollforward of the fair value of the Company’s investments whose fair value was determined using Level 3 inputs at September 30, 2014:

(In thousands)	Fair Value
Balance, January 1, 2014	$	1,526
Total unrealized losses included in other comprehensive (loss) income	(383		)
Sale of equity securities	(1,143		)
Balance, September 30, 2014	$	—

As disclosed in Note 3, Investments, during the three months ended June 30, 2014, the Company sold its Level 3 investment, which consisted of warrants to purchase the common stock of Acceleron.

The Company’s investments in U.S. government and agency debt securities, international government agency debt securities and corporate debt securities classified as Level 2 within the fair value hierarchy were initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing market-observable data. The market-observable data included reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. The Company validated the prices developed using the market-observable data by obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active.

The carrying amounts reflected in the Condensed Consolidated Balance Sheets for cash and cash equivalents, accounts receivable, other current assets, accounts payable and accrued expenses approximate fair value due to their short-term nature. The fair value of the remaining financial instruments not currently recognized at fair value on the Company’s Condensed Consolidated Balance Sheets consisted of the $300.0 million, seven-year term loan bearing interest at LIBOR plus 2.75% with a LIBOR floor of 0.75% (“Term Loan B-1”) and the $75.0 million, four-year term loan bearing interest at LIBOR plus 2.75%, with no LIBOR floor (“Term Loan B-2” and together with Term Loan B-1, the “Term Loan Facility”). The estimated fair value of these term loans, which was based on quoted market price indications (Level 2 in the fair value hierarchy) and may not be representative of actual values that could have been or will be realized in the future, was as follows at September 30, 2014:

	Carrying		Estimated
(In thousands)	Value		Fair Value
Term Loan B-1	$	292,130	$	289,346
Term Loan B-2	$	67,421	$	66,825

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

INVENTORY

9 Months Ended

Sep. 30, 2014

INVENTORY

INVENTORY

5. INVENTORY

Inventory is stated at the lower of cost or market value. Cost is determined using the first-in, first-out method. Inventory consisted of the following:

	September 30,		December 31,
(In thousands)	2014		2013
Raw materials	$	18,594	$	18,410
Work in process	24,106		15,581
Finished goods	7,771		12,227
Total inventory	$	50,471	$	46,218

PROPERTY, PLANT AND EQUIPMENT

9 Months Ended

Sep. 30, 2014

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT

6. PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consisted of the following:

	September 30,			December 31,
(In thousands)	2014			2013
Land	$	8,163		$	8,440
Building and improvements	148,856			148,044
Furniture, fixture and equipment	231,426			220,984
Leasehold improvements	24,251			23,980
Construction in progress	32,462			26,688
Subtotal	445,158			428,136
Less: accumulated depreciation	(183,030		)	(153,646		)
Total property, plant and equipment, net	$	262,128		$	274,490

In April 2014, the Company sold certain of its land, buildings and equipment at its Athlone, Ireland facility that had a carrying value of $2.2 million, in exchange for $17.5 million. $3.0 million of the sale proceeds will remain in escrow pending the completion of certain additional services the Company is obligated to perform, and will be recognized as “Gain on sale of property, plant and equipment” as the services are provided.

GOODWILL AND INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2014

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS

7. GOODWILL AND INTANGIBLE ASSETS

Goodwill and intangible assets consisted of the following:

		September 30, 2014
	Weighted	Gross		Accumulated			Net
(In thousands)	Amortizable Life	Carrying Amount		Amortization			Carrying Amount
Goodwill		$	92,740	$	—		$	92,740

Finite-lived intangible assets:
Collaboration agreements	12	$	499,700	$	(115,102	)	$	384,598
NanoCrystal technology	13	74,600		(12,001		)	62,599
OCR technology	12	66,300		(18,841		)	47,459
Total		$	640,600	$	(145,944	)	$	494,656

Based on the Company’s most recent analysis, amortization of intangible assets included within its Condensed Consolidated Balance Sheets at September 30, 2014 is expected to be approximately $60.0 million, $65.0 million, $70.0 million, $70.0 million and $70.0 million in the years ending December 31, 2014 through 2018, respectively. Although the Company believes such available information and assumptions are reasonable, given the inherent risks and uncertainties underlying its expectations regarding such future revenues, there is the potential for the Company’s actual results to vary significantly from such expectations. If revenues are projected to change, the related amortization of the intangible assets will change in proportion to the change in revenues.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

9 Months Ended

Sep. 30, 2014

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

8. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consisted of the following:

	September 30,		December 31,
(In thousands)	2014		2013
Accounts payable	$	27,233	$	19,493
Accrued compensation	25,121		28,101
Accrued restructuring	4,268		7,296
Accrued other	43,707		36,283
Total accounts payable and accrued expenses	$	100,329	$	91,173

RESTRUCTURING

9 Months Ended

Sep. 30, 2014

RESTRUCTURING

RESTRUCTURING

9. RESTRUCTURING

On April 4, 2013, the Company approved a restructuring plan at its Athlone, Ireland manufacturing facility consistent with the evolution of the Company’s product portfolio and designed to improve operational performance for the future. The restructuring plan calls for the Company to terminate manufacturing services for certain older products that are expected to no longer be economically practicable to produce due to decreasing demand from its customers resulting from generic competition. The Company expects to continue to generate revenues from the manufacturing of these products through the year ending December 31, 2015.

As a result of the termination of these services, the Company also implemented a corresponding reduction in headcount of up to 130 employees. In connection with this restructuring plan, during the twelve months ended March 31, 2013, the Company recorded a restructuring charge of $12.3 million, which consisted of severance and outplacement services. The Company has paid in cash $8.6 million and recorded an adjustment of $0.1 million due to changes in foreign currency since inception of this restructuring plan. Restructuring activity during the nine months ended September 30, 2014 was as follows:

	Severance and
(In thousands)	Outplacement Services
Balance, January 1, 2014	$	10,578
Payments	(6,320		)
Adjustments	(441		)
Balance, September 30, 2014	$	3,817

At September 30, 2014 and December 31, 2013, $3.8 million and $6.8 million, respectively, of this restructuring accrual was included within “Accounts payable and accrued expenses,” and none and $3.8 million, respectively, was included within “Other long-term liabilities” in the accompanying Condensed Consolidated Balance Sheets.

LONG-TERM DEBT

9 Months Ended

Sep. 30, 2014

LONG-TERM DEBT

LONG-TERM DEBT

10. LONG-TERM DEBT

Long-term debt consisted of the following:

	September 30,			December 31,
(In thousands)	2014			2013
Term Loan B-1, due September 25, 2019	$	292,130		$	294,091
Term Loan B-2, due September 25, 2016	67,421			70,202
Total	359,551			364,293
Less: current portion	(6,750		)	(6,750		)
Long-term debt	$	352,801		$	357,543

DERIVATIVE INSTRUMENTS

9 Months Ended

Sep. 30, 2014

DERIVATIVE INSTRUMENTS

DERIVATIVE INSTRUMENTS

11. DERIVATIVE INSTRUMENTS

In September 2011, the Company entered into an interest rate swap agreement with Morgan Stanley Capital Services LLC to mitigate the impact of fluctuations in the three-month LIBOR rate at which the Company’s long-term debt bears interest. The interest rate swap agreement became effective in December 2012, had a notional value of $65.0 million and expired in September 2014. The Company recorded an immaterial loss and a gain of $0.1 million within “Other income (expense), net” due to the change in fair value of this contract during the nine months ended September 30, 2014 and 2013, respectively. The fair value and presentation in the Condensed Consolidated Balance Sheets for the Company’s interest rate swap was as follows:

		Fair Value
(In thousands)	Balance Sheet Location	September 30, 2014		December 31, 2013
Liability derivative not designated as a cash flow hedge	Other long-term liabilities	$	—	$	(275	)

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41635-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5580258-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624181-113959

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41638-113959

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

SHARE-BASED COMPENSATION

9 Months Ended

Sep. 30, 2014

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION

12. SHARE-BASED COMPENSATION

Share-based compensation expense consisted of the following:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2014		2013		2014		2013
Cost of goods manufactured and sold	$	1,557	$	1,149	$	5,636	$	3,223
Research and development	3,403		2,825		10,886		7,129
Selling, general and administrative	8,521		10,235		29,718		20,547
Total share-based compensation expense	$	13,481	$	14,209	$	46,240	$	30,899

At September 30, 2014 and December 31, 2013, $0.7 million and $0.4 million, respectively, of share-based compensation cost was capitalized and recorded as “Inventory” in the accompanying Condensed Consolidated Balance Sheets.

SHAREHOLDERS' EQUITY	9 Months Ended
SHAREHOLDERS' EQUITY	Sep. 30, 2014
SHAREHOLDERS' EQUITY
SHAREHOLDERS' EQUITY	13. SHAREHOLDERS’ EQUITY In January 2014, the Company sold 5,917,160 ordinary shares, $0.01 par value per share, pursuant to its shelf registration statement on Form S-3 at a price of $42.25 per share. The Company received total gross proceeds of $250.0 million, before deducting expenses of $1.6 million associated with the ordinary share sale.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

(LOSS) EARNINGS PER SHARE

9 Months Ended

Sep. 30, 2014

EARNINGS (LOSS) PER SHARE

(LOSS) EARNINGS PER SHARE

14. (LOSS) EARNINGS PER SHARE

Basic (loss) earnings per ordinary share is calculated based upon net (loss) income available to holders of ordinary shares divided by the weighted average number of shares outstanding. For the calculation of diluted (loss) earnings per ordinary share, the Company uses the weighted average number of ordinary shares outstanding, as adjusted for the effect of potential outstanding shares, including stock options and restricted stock units.

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
(In thousands)	2014			2013			2014			2013
Numerator:
Net (loss) income	$	(39,956	)	$	(7,762	)	$	(60,575	)	$	2,569
Denominator:
Weighted average number of ordinary shares outstanding	145,896			136,106			144,732			134,670
Effect of dilutive securities:
Stock options	—			—			—			6,929
Restricted stock units	—			—			—			1,423
Dilutive ordinary share equivalents	—			—			—			8,352
Shares used in calculating diluted earnings (loss) per share	145,896			136,106			144,732			143,022

The following potential ordinary equivalent shares have not been included in the net (loss) income per ordinary share calculation because the effect would have been anti-dilutive:

	Three Months Ended		Nine Months Ended
	September 30,		September 30,
(In thousands)	2014	2013	2014	2013
Stock options	9,721	9,241	9,605	1,084
Restricted stock units	1,683	1,229	1,821	—
Total	11,404	10,470	11,426	1,084

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2014
INCOME TAXES
INCOME TAXES	15. INCOME TAXES The Company recorded an income tax provision of $3.5 million and $5.8 million for the three and nine months ended September 30, 2014, respectively and an income tax provision of $0.2 million and $7.8 million for the three and nine months ended September 30, 2013, respectively. The income tax provision in the three and nine months ended September 30, 2014 primarily relates to U.S. federal and state taxes on income, partially offset by deferred tax benefits in Ireland. The income tax provision in the three and nine months ended September 30, 2013 primarily relates to U.S. federal and state taxes on income, partially offset by a discrete benefit of $3.0 million from the settlement of uncertain tax benefits. The Company records a deferred tax asset or liability based on the difference between the financial statement and tax basis of its assets and liabilities, as measured by enacted jurisdictional tax rates assumed to be in effect when these differences reverse. At September 30, 2014, the Company maintained a valuation allowance against certain of its U.S. and foreign deferred tax assets. The Company evaluates, at each reporting period, the need for a valuation allowance on its deferred tax assets on a jurisdiction by jurisdiction basis.

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2014
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	16. COMMITMENTS AND CONTINGENCIES From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. For example, the Company is currently involved in various Paragraph IV lawsuits in the U.S. and other proceedings outside of the U.S. involving its patents in respect of FOCALIN XR, TRICOR, MEGACE ES, AMPYRA and ZOHYDRO ER. The Company is not aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition, cash flows and results of operations.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements of the Company for the three and nine months ended September 30, 2014 and 2013 are unaudited and have been prepared on a basis substantially consistent with the audited financial statements for the nine-month transition period ended December 31, 2013 (the “Transition Period”). The year-end Condensed Consolidated Balance Sheet data, which is presented for comparative purposes, was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (“U.S.”) (commonly referred to as “GAAP”). In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, that are necessary to present fairly the results of operations for the reported periods. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto of Alkermes, which are contained in the Company’s Transition Report on Form 10-KT, which has been filed with the SEC. The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period, including the Transition Period, or for a full fiscal year.
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include the accounts of Alkermes plc and its wholly owned subsidiaries as disclosed in Note 2: Summary of Significant Accounting Policies within Part II, Item 8 of our Transition Report. During the nine months ended September 30, 2014, the following wholly owned subsidiaries were added:Alkermes Science Three Limited; Alkermes Science Four Limited; Alkermes Science Five Limited; and Alkermes Science Six Limited. Intercompany accounts and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates and judgments and methodologies, including those related to revenue recognition and related allowances, its collaborative relationships, clinical trial expenses, the valuation of inventory, impairment and amortization of intangibles and long-lived assets, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of investments and derivative instruments, litigation and restructuring charges. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.
Segment Information	Segment Information The Company operates as one business segment, which is the business of developing, manufacturing and commercializing medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious diseases. The Company’s chief decision maker, the Chairman and Chief Executive Officer, reviews the Company’s operating results on an aggregate basis and manages the Company’s operations as a single operating unit.
New Accounting Pronouncements	New Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard-setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. In July 2013, the FASB adopted clarifying guidance on the presentation of unrecognized tax benefits when various qualifying tax credits exist. The amendment requires that unrecognized tax benefits be presented on the consolidated balance sheet as a reduction to deferred tax assets created by net operating losses (‘‘NOLs’’) or other tax credits from prior periods that occur in the same taxing jurisdiction. To the extent that the unrecognized tax benefit exceeds these NOLs or other tax credits, it shall be presented as a liability. This update, required to be adopted for all annual periods and interim reporting periods beginning after December 15, 2013, was adopted by the Company on January 1, 2014. The adoption of this standard did not have a material impact on the presentation of the Company’s financial position. In April 2014, the FASB adopted guidance that amends the requirements for reporting discontinued operations. Under the amendment, only those disposals of components of an entity that represent a strategic shift that has (or will have) a major effect on an entity's operations and financial results will be reported as discontinued operations in the financial statements. Currently, many disposals, some of which may be routine in nature and not a change in an entity's strategy, are reported in discontinued operations. The guidance also requires expanded disclosures for discontinued operations. This guidance becomes effective for the Company in its year ending December 31, 2015 and early adoption is permitted, but only for disposals that have not been reported in financial statements previously issued or available for issuance. The adoption of this standard is not expected to have a material impact on the Company's results of operations, cash flows or financial condition. In June 2014, the FASB issued guidance that clarifies the accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period. Existing GAAP does not contain explicit guidance on how to account for these share-based payments. The new guidance requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. Entities have the option of prospectively applying the guidance to awards granted or modified after the effective date or retrospectively applying the guidance to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements. The guidance becomes effective for the Company in its year ending December 31, 2016, and early adoption is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. In May 2014, the FASB issued guidance that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. The guidance becomes effective for the Company in its year ending December 31, 2017, and early adoption is not permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

- Definition

Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

+ References + Details

INVESTMENTS (Tables)

9 Months Ended

Sep. 30, 2014

INVESTMENTS

Schedule of investments

			Gross Unrealized
					Losses
	Amortized				Less than			Greater than			Estimated
	Cost		Gains		One Year			One Year			Fair Value
	(In thousands)
September 30, 2014
Short-term investments:
Available-for-sale securities:
U.S. government and agency debt securities	$	220,312	$	170	$	—		$	—		$	220,482
Corporate debt securities	178,312		97		(46		)	—			178,363
International government agency debt securities	36,321		20		—			—			36,341
	434,945		287		(46		)	—			435,186
Money market funds	1,201		—		—			—			1,201
Total short-term investments	436,146		287		(46		)	—			436,387
Long-term investments:
Available-for-sale securities:
U.S. government and agency debt securities	101,464		—		(163		)	(22		)	101,279
Corporate debt securities	31,390		—		(37		)	(4		)	31,349
International government agency debt securities	9,577		—		(4		)	(1		)	9,572
	142,431		—		(204		)	(27		)	142,200
Held-to-maturity securities:
Certificates of deposit	1,547		—		—			—			1,547
Total long-term investments	143,978		—		(204		)	(27		)	143,747
Total investments	$	580,124	$	287	$	(250	)	$	(27	)	$	580,134

December 31, 2013
Short-term investments:
Available-for-sale securities:
U.S. government and agency debt securities	$	130,669	$	80	$	(1	)	$	—		$	130,748
Corporate debt securities	38,614		64		(30		)	—			38,648
International government agency debt securities	24,097		8		(33		)	—			24,072
	193,380		152		(64		)	—			193,468
Money market funds	1,201		—		—			—			1,201
Total short-term investments	194,581		152		(64		)	—			194,669
Long-term investments:
Available-for-sale securities:
Equity securities	8,732		21,253		—			—			29,985
U.S. government and agency debt securities	28,503		—		(61		)	(3		)	28,439
Corporate debt securities	20,266		—		(30		)	(75		)	20,161
International government agency debt securities	7,691		—		(5		)	—			7,686
	65,192		21,253		(96		)	(78		)	86,271
Held-to-maturity securities:
Certificates of deposit	1,493		—		—			—			1,493
Total long-term investments	66,685		21,253		(96		)	(78		)	87,764
Total investments	$	261,266	$	21,405	$	(160	)	$	(78	)	$	282,433

Proceeds from the sales and maturities of marketable securities, plus the resulting realized gains and losses

	Nine Months Ended
	September 30,
(In thousands)	2014			2013
Proceeds from the sales and maturities of marketable securities	$	246,540		$	95,149
Realized gains	$	15,352		$	54
Realized losses	$	(10	)	$	(5	)

The cost and fair value of available-for-sale and held-to-maturity securities by contractual maturity

	Available-for-sale				Held-to-maturity
	Amortized		Estimated		Amortized		Estimated
(In thousands)	Cost		Fair Value		Cost		Fair Value
Within 1 year	$	298,878	$	298,972	$	1,547	$	1,547
After 1 year through 5 years	278,498		278,414		—		—
Total	$	577,376	$	577,386	$	1,547	$	1,547

FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Sep. 30, 2014

FAIR VALUE MEASUREMENTS

Summary of the Company's assets and liabilities measured at fair value on a recurring basis

	September 30,
(In thousands)	2014		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	1,201	$	1,201	$	—	$	—
U.S. government and agency debt securities	321,761		169,120		152,641		—
Corporate debt securities	209,712		—		209,712		—
International government agency debt securities	45,913		—		45,913		—
Total	$	578,587	$	170,321	$	408,266	$	—

	December 31,
	2013			Level 1		Level 2			Level 3
Assets:
Cash equivalents	$	1,201		$	1,201	$	—		$	—
U.S. government and agency debt securities	159,187			63,213		95,974			—
Corporate debt securities	58,809			—		58,809			—
International government agency debt securities	31,758			—		31,758			—
Equity securities	29,985			28,459		—			1,526
Total	$	280,940		$	92,873	$	186,541		$	1,526

Liabilities:
Interest rate swap contract	$	(275	)	$	—	$	(275	)	$	—
Total	$	(275	)	$	—	$	(275	)	$	—

Schedule of rollforward of the fair value of the Company's investments whose fair value was determined using Level 3 inputs

(In thousands)	Fair Value
Balance, January 1, 2014	$	1,526
Total unrealized losses included in other comprehensive (loss) income	(383		)
Sale of equity securities	(1,143		)
Balance, September 30, 2014	$	—

Estimated fair value of term loans

The estimated fair value of these term loans, which was based on quoted market price indications (Level 2 in the fair value hierarchy) and may not be representative of actual values that could have been or will be realized in the future, was as follows at September 30, 2014:

	Carrying		Estimated
(In thousands)	Value		Fair Value
Term Loan B-1	$	292,130	$	289,346
Term Loan B-2	$	67,421	$	66,825

INVENTORY (Tables)

9 Months Ended

Sep. 30, 2014

INVENTORY

Schedule of inventories

	September 30,		December 31,
(In thousands)	2014		2013
Raw materials	$	18,594	$	18,410
Work in process	24,106		15,581
Finished goods	7,771		12,227
Total inventory	$	50,471	$	46,218

PROPERTY, PLANT AND EQUIPMENT (Tables)

9 Months Ended

Sep. 30, 2014

PROPERTY, PLANT AND EQUIPMENT

Schedule of property, plant and equipment

	September 30,			December 31,

(In thousands)	2014			2013
Land	$	8,163		$	8,440
Building and improvements	148,856			148,044
Furniture, fixture and equipment	231,426			220,984
Leasehold improvements	24,251			23,980
Construction in progress	32,462			26,688
Subtotal	445,158			428,136
Less: accumulated depreciation	(183,030		)	(153,646		)
Total property, plant and equipment, net	$	262,128		$	274,490

GOODWILL AND INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2014

GOODWILL AND INTANGIBLE ASSETS

Schedule of goodwill and intangible assets

		September 30, 2014
	Weighted	Gross		Accumulated			Net
(In thousands)	Amortizable Life	Carrying Amount		Amortization			Carrying Amount
Goodwill		$	92,740	$	—		$	92,740

Finite-lived intangible assets:
Collaboration agreements	12	$	499,700	$	(115,102	)	$	384,598
NanoCrystal technology	13	74,600		(12,001		)	62,599
OCR technology	12	66,300		(18,841		)	47,459
Total		$	640,600	$	(145,944	)	$	494,656

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)

9 Months Ended

Sep. 30, 2014

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Schedule of accounts payable and accrued expenses

	September 30,		December 31,
(In thousands)	2014		2013
Accounts payable	$	27,233	$	19,493
Accrued compensation	25,121		28,101
Accrued restructuring	4,268		7,296
Accrued other	43,707		36,283
Total accounts payable and accrued expenses	$	100,329	$	91,173

RESTRUCTURING (Tables)

9 Months Ended

Sep. 30, 2014

RESTRUCTURING

Schedule of restructuring charges recorded

	Severance and
(In thousands)	Outplacement Services
Balance, January 1, 2014	$	10,578
Payments	(6,320		)
Adjustments	(441		)
Balance, September 30, 2014	$	3,817

LONG-TERM DEBT (Tables)

9 Months Ended

Sep. 30, 2014

LONG-TERM DEBT

Schedule of long-term debt

	September 30,			December 31,
(In thousands)	2014			2013
Term Loan B-1, due September 25, 2019	$	292,130		$	294,091
Term Loan B-2, due September 25, 2016	67,421			70,202
Total	359,551			364,293
Less: current portion	(6,750		)	(6,750		)
Long-term debt	$	352,801		$	357,543

DERIVATIVE INSTRUMENTS (Tables)

9 Months Ended

Sep. 30, 2014

DERIVATIVE INSTRUMENTS

Schedule of fair value and presentation in the condensed consolidated balance sheets for derivatives designated and not designated as hedging instruments

		Fair Value
(In thousands)	Balance Sheet Location	September 30, 2014		December 31, 2013
Liability derivative not designated as a cash flow hedge	Other long-term liabilities	$	—	$	(275	)

SHARE-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2014

SHARE-BASED COMPENSATION

Schedule of share-based compensation expense

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2014		2013		2014		2013
Cost of goods manufactured and sold	$	1,557	$	1,149	$	5,636	$	3,223
Research and development	3,403		2,825		10,886		7,129
Selling, general and administrative	8,521		10,235		29,718		20,547
Total share-based compensation expense	$	13,481	$	14,209	$	46,240	$	30,899

(LOSS) EARNINGS PER SHARE (Tables)

9 Months Ended

Sep. 30, 2014

EARNINGS (LOSS) PER SHARE

Schedule of weighted average number of ordinary shares outstanding, as adjusted for the effect of potential outstanding shares, including stock options and restricted stock units

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
(In thousands)	2014			2013			2014			2013
Numerator:
Net (loss) income	$	(39,956	)	$	(7,762	)	$	(60,575	)	$	2,569
Denominator:
Weighted average number of ordinary shares outstanding	145,896			136,106			144,732			134,670
Effect of dilutive securities:
Stock options	—			—			—			6,929
Restricted stock units	—			—			—			1,423
Dilutive ordinary share equivalents	—			—			—			8,352
Shares used in calculating diluted earnings (loss) per share	145,896			136,106			144,732			143,022

Schedule of anti-dilutive potential ordinary equivalent shares excluded from calculation of net income (loss) per share

	Three Months Ended		Nine Months Ended
	September 30,		September 30,
(In thousands)	2014	2013	2014	2013
Stock options	9,721	9,241	9,605	1,084
Restricted stock units	1,683	1,229	1,821	—
Total	11,404	10,470	11,426	1,084

THE COMPANY (Details)	9 Months Ended
THE COMPANY (Details)	Sep. 30, 2014 product
THE COMPANY
Minimum number of commercial drug products in Company's diversified portfolio	20

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Sep. 30, 2014 item
Segment Information
Number of business segments	1

INVESTMENTS (Details) - USD ($) $ in Thousands	Sep. 30, 2014	Dec. 31, 2013
Available-for-sale securities:
Amortized Cost	$ 580,124	$ 261,266
Gross Unrealized Gains	287	21,405
Gross Unrealized Losses, Less than One Year	(250)	(160)
Gross Unrealized Losses, Greater than One Year	(27)	(78)
Held-to-maturity securities:
Estimated Fair Value	1,547
Total investments
Estimated Fair Value	580,134	282,433
Short-term investments
Available-for-sale securities:
Amortized Cost	434,945	193,380
Gross Unrealized Gains	287	152
Gross Unrealized Losses, Less than One Year	(46)	(64)
Estimated Fair Value	435,186	193,468
Held-to-maturity securities:
Amortized Cost	436,146	194,581
Gross Unrealized Gains	(287)	(152)
Gross Unrealized Losses, Less than One Year	(46)	(64)
Total investments
Estimated Fair Value	436,387	194,669
Short-term investments \| Money market funds
Available-for-sale securities:
Amortized Cost	1,201	1,201
Estimated Fair Value	1,201	1,201
Short-term investments \| U.S. government and agency debt securities
Available-for-sale securities:
Amortized Cost	220,312	130,669
Gross Unrealized Gains	170	80
Gross Unrealized Losses, Less than One Year		(1)
Estimated Fair Value	220,482	130,748
Short-term investments \| Corporate debt securities
Available-for-sale securities:
Amortized Cost	178,312	38,614
Gross Unrealized Gains	97	64
Gross Unrealized Losses, Less than One Year	(46)	(30)
Estimated Fair Value	178,363	38,648
Short-term investments \| International government agency debt securities
Available-for-sale securities:
Amortized Cost	36,321	24,097
Gross Unrealized Gains	20	8
Gross Unrealized Losses, Less than One Year		(33)
Estimated Fair Value	36,341	24,072
Long-term investments
Available-for-sale securities:
Amortized Cost	142,431	65,192
Gross Unrealized Gains		21,253
Gross Unrealized Losses, Less than One Year	(204)	(96)
Gross Unrealized Losses, Greater than One Year	(27)	(78)
Estimated Fair Value	142,200	86,271
Held-to-maturity securities:
Amortized Cost	143,978	66,685
Gross Unrealized Gains		(21,253)
Gross Unrealized Losses, Less than One Year	(204)	(96)
Gross Unrealized Losses, Greater than One Year	(27)	(78)
Total investments
Estimated Fair Value	143,747	87,764
Long-term investments \| Certificates of deposit
Available-for-sale securities:
Amortized Cost	1,547	1,493
Total investments
Estimated Fair Value	1,547	1,493
Long-term investments \| Equity securities
Available-for-sale securities:
Amortized Cost		8,732
Gross Unrealized Gains		21,253
Estimated Fair Value		29,985
Long-term investments \| U.S. government and agency debt securities
Available-for-sale securities:
Amortized Cost	101,464	28,503
Gross Unrealized Losses, Less than One Year	(163)	(61)
Gross Unrealized Losses, Greater than One Year	(22)	(3)
Estimated Fair Value	101,279	28,439
Long-term investments \| Corporate debt securities
Available-for-sale securities:
Amortized Cost	31,390	20,266
Gross Unrealized Losses, Less than One Year	(37)	(30)
Gross Unrealized Losses, Greater than One Year	(4)	(75)
Estimated Fair Value	31,349	20,161
Long-term investments \| International government agency debt securities
Available-for-sale securities:
Amortized Cost	9,577	7,691
Gross Unrealized Losses, Less than One Year	(4)	(5)
Gross Unrealized Losses, Greater than One Year	(1)
Estimated Fair Value	$ 9,572	$ 7,686

INVESTMENTS (Details 2) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
INVESTMENTS (Details 2) - USD ($) $ in Thousands	Jun. 30, 2014	Sep. 30, 2014	Sep. 30, 2013
INVESTMENTS
Proceeds from the sales and maturities of marketable securities		$ 246,540	$ 95,149
Realized gains		15,352	54
Realized losses		(10)	$ (5)
Proceeds from sale of investments in Acceleron Pharma Inc.	$ 24,000
Realized gain on sale of investment in Acceleron Pharma Inc.		$ 15,296

INVESTMENTS (Details 3) $ in Thousands	Sep. 30, 2014 USD ($)
Available-for-sale, Amortized Cost
Within 1 year	$ 298,878
After 1 year through 5 years	278,498
Total	577,376
Available-for-sale, Estimated Fair Value
Within 1 year	298,972
After 1 year through 5 years	278,414
Total	577,386
Held-to-maturity, Amortized Cost
Within 1 year	1,547
Total	1,547
Held-to-maturity, Estimated Fair Value
Within 1 year	1,547
Estimated Fair Value	$ 1,547

INVESTMENTS (Details 4) $ in Thousands, € in Millions	1 Months Ended	9 Months Ended
INVESTMENTS (Details 4) $ in Thousands, € in Millions	Oct. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2013 USD ($)	May 31, 2014 EUR (€)	May 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Equity method investment
Gain on sale of property, plant and equipment		$ 11,942	$ (391)
Civitas
Equity method investment
Carrying value of equity investment		0				$ 2,000
Reduction in carrying value of investment of the entity, which represents the Company's share of investee's net losses		2,000
Increase in carrying value of equity method investment		$ 1,000
Fountain Healthcare Partners II, LP of Ireland
Equity method investment
Carrying value of equity investment				€ 0.9	$ 1,200
Amount committed \| €				€ 7.4
Funding commitment as percentage of partnership's total funding				10.00%	10.00%
Acorda Therpeutics, Inc
Equity method investment
Ownership percentage	6.00%
Acquisition cost of Civitas	$ 525,000
Gain on sale of property, plant and equipment	30,000
Proceeds from release of escrow amounts	27,200
Acorda Therpeutics, Inc \| Subsequent event
Equity method investment
Proceeds from release of escrow amounts	$ 2,300

FAIR VALUE MEASUREMENTS (Details) - Recurring basis - USD ($) $ in Thousands	Sep. 30, 2014	Dec. 31, 2013
Level 1
Fair value
Assets, Total	$ 170,321	$ 92,873
Level 2
Fair value
Assets, Total	408,266	186,541
Liabilities, Total		(275)
Level 3
Fair value
Assets, Total		1,526
Total
Fair value
Assets, Total	578,587	280,940
Liabilities, Total		(275)
Interest rate swap contract \| Level 2
Fair value
Interest rate swap contract		(275)
Interest rate swap contract \| Total
Fair value
Interest rate swap contract		(275)
Cash equivalents \| Level 1
Fair value
Available for sale securities	1,201	1,201
Cash equivalents \| Total
Fair value
Available for sale securities	1,201	1,201
U.S. government and agency debt securities \| Level 1
Fair value
Available for sale securities	169,120	63,213
U.S. government and agency debt securities \| Level 2
Fair value
Available for sale securities	152,641	95,974
U.S. government and agency debt securities \| Total
Fair value
Available for sale securities	321,761	159,187
Corporate debt securities \| Level 2
Fair value
Available for sale securities	209,712	58,809
Corporate debt securities \| Total
Fair value
Available for sale securities	209,712	58,809
International government agency debt securities \| Level 2
Fair value
Available for sale securities	45,913	31,758
International government agency debt securities \| Total
Fair value
Available for sale securities	$ 45,913	31,758
Equity securities \| Level 1
Fair value
Available for sale securities		28,459
Equity securities \| Level 3
Fair value
Available for sale securities		1,526
Equity securities \| Total
Fair value
Available for sale securities		$ 29,985

FAIR VALUE MEASUREMENTS (Details 2) $ in Thousands	9 Months Ended
FAIR VALUE MEASUREMENTS (Details 2) $ in Thousands	Sep. 30, 2014 USD ($) item
Roll forward of the fair value of the Company's investments whose fair value was determined using Level 3 inputs
Number of investments transferred from level 1 to level 2 \| item	0
Number of investments transferred from level 2 to level 1 \| item	0
Balance at the beginning of the period	$ 1,526
Total unrealized losses included in other comprehensive (loss) income	(383)
Sale of equity securities	$ (1,143)

FAIR VALUE MEASUREMENTS (Details 3) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Estimated fair value of the Term Loans
Carrying Value	$ 359,551	$ 364,293
Term Loan B-1
Estimated fair value of the Term Loans
Fair value of remaining financial instruments not recognized at fair value	$ 300,000
Term loans maturity period	7 years
Variable interest rate base	LIBOR
Carrying Value	$ 292,130	294,091
Estimated Fair Value	289,346
Term Loan B-2
Estimated fair value of the Term Loans
Fair value of remaining financial instruments not recognized at fair value	$ 75,000
Term loans maturity period	4 years
Variable interest rate base	LIBOR
Carrying Value	$ 67,421	$ 70,202
Estimated Fair Value	$ 66,825
LIBOR \| Term Loan B-1
Estimated fair value of the Term Loans
Interest rate added to base rate (as a percent)	2.75%
Interest rate, variable interest rate floor (as a percent)	0.75%
LIBOR \| Term Loan B-2
Estimated fair value of the Term Loans
Interest rate added to base rate (as a percent)	2.75%
Interest rate, variable interest rate floor (as a percent)	0.00%

INVENTORY (Details) - USD ($) $ in Thousands	Sep. 30, 2014	Dec. 31, 2013
INVENTORY
Raw materials	$ 18,594	$ 18,410
Work in process	24,106	15,581
Finished goods	7,771	12,227
Total inventory	$ 50,471	$ 46,218

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Apr. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Property, plant and equipment
Subtotal		$ 445,158		$ 428,136
Less: accumulated depreciation		(183,030)		(153,646)
Total property, plant and equipment, net		262,128		274,490
Proceeds from sale of property, plant and equipment		14,361	$ 125
Athlone, Ireland manufacturing facility
Property, plant and equipment
Carrying value at the time of sold	$ 2,200
Proceeds from sale of property, plant and equipment	17,500
Proceeds from sale of property, plant and equipment which remain in escrow account	$ 3,000
Land
Property, plant and equipment
Subtotal		8,163		8,440
Buildings and improvements
Property, plant and equipment
Subtotal		148,856		148,044
Furniture, fixtures and equipment
Property, plant and equipment
Subtotal		231,426		220,984
Leasehold improvements
Property, plant and equipment
Subtotal		24,251		23,980
Construction in progress
Property, plant and equipment
Subtotal		$ 32,462		$ 26,688

GOODWILL AND INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Intangible assets
Gross Carrying Amount	$ 92,740
Goodwill	92,740	$ 92,740
Finite-lived intangible assets:
Gross Carrying Amount	640,600
Accumulated Amortization	(145,944)
Net Carrying Amount	$ 494,656
Collaboration agreements
Finite-lived intangible assets:
Weighted Amortizable Life	12 years
Gross Carrying Amount	$ 499,700
Accumulated Amortization	(115,102)
Net Carrying Amount	$ 384,598
NanoCrystal technology
Finite-lived intangible assets:
Weighted Amortizable Life	13 years
Gross Carrying Amount	$ 74,600
Accumulated Amortization	(12,001)
Net Carrying Amount	$ 62,599
OCR technology
Finite-lived intangible assets:
Weighted Amortizable Life	12 years
Gross Carrying Amount	$ 66,300
Accumulated Amortization	(18,841)
Net Carrying Amount	$ 47,459

GOODWILL AND INTANGIBLE ASSETS (Details 2) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
GOODWILL AND INTANGIBLE ASSETS
Amortization expense	$ 15,244	$ 12,856	$ 42,909	$ 35,894
Expected amortization of intangible assets
2014	60,000		60,000
2015	65,000		65,000
2016	70,000		70,000
2017	70,000		70,000
2018	$ 70,000		$ 70,000

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Sep. 30, 2014	Dec. 31, 2013	Mar. 31, 2013
ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Accounts payable	$ 27,233	$ 19,493
Accrued compensation	25,121	28,101
Accrued restructuring	4,268	7,296	$ 12,300
Accrued other	43,707	36,283
Total accounts payable and accrued expenses	$ 100,329	$ 91,173

RESTRUCTURING (Details) $ in Thousands	9 Months Ended
RESTRUCTURING (Details) $ in Thousands	Sep. 30, 2014 USD ($) item	Sep. 30, 2013 USD ($)	Mar. 31, 2013 USD ($)
Restructuring activity
Cash paid for restructuring costs	$ 8,600
Foreign currency adjustment	100
Restructuring activity
Balance at beginning of the period	7,296
Payments		$ (12,300)
Balance at end of the period	4,268
Restructuring accrual
Restructuring accrual	7,296		$ 12,300
Accounts payable and accrued expenses.
Restructuring activity
Balance at beginning of the period	6,800
Balance at end of the period	3,800
Restructuring accrual
Restructuring accrual	6,800
Other long-term liabilities
Restructuring activity
Balance at beginning of the period	3,800
Balance at end of the period	0
Restructuring accrual
Restructuring accrual	$ 3,800
Athlone, Ireland manufacturing facility \| Maximum
Restructuring activity
Number of employees eliminated \| item	130
Severance and outplacement services
Restructuring activity
Balance at beginning of the period	$ 10,578
Payments	(6,320)
Adjustments	(441)
Balance at end of the period	3,817
Restructuring accrual
Restructuring accrual	$ 10,578

LONG-TERM DEBT (Details) - USD ($) $ in Thousands	Sep. 30, 2014	Dec. 31, 2013
Long-term debt
Total	$ 359,551	$ 364,293
Less: current portion	(6,750)	(6,750)
LONG-TERM DEBT	352,801	357,543
Term Loan B-1
Long-term debt
Total	292,130	294,091
Term Loan B-2
Long-term debt
Total	$ 67,421	$ 70,202

DERIVATIVE INSTRUMENTS (Details) - Interest rate swap contract - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Sep. 30, 2011
Derivative instruments
Variable interest rate base	three-Month LIBOR
Notional value				$ 65,000
Loss (gain) on derivative instrument due to change in fair value of the contract	$ 100	$ (100)
Not designated as hedging instrument
Derivative instruments
Fair value of derivative instrument			$ (275)

SHARE-BASED COMPENSATION (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
SHARE-BASED COMPENSATION (Details) - USD ($) $ in Thousands	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Share-based Compensation Expense
Total share-based compensation expense	$ 13,481	$ 14,209	$ 46,240	$ 30,899
Share based compensation cost capitalized			700		$ 400
Cost of goods manufactured and sold
Share-based Compensation Expense
Total share-based compensation expense	1,557	1,149	5,636	3,223
Research and development
Share-based Compensation Expense
Total share-based compensation expense	3,403	2,825	10,886	7,129
Selling, general and administrative
Share-based Compensation Expense
Total share-based compensation expense	$ 8,521	$ 10,235	$ 29,718	$ 20,547

SHAREHOLDERS' EQUITY (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	9 Months Ended
	Jan. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
SHAREHOLDERS' EQUITY
Number of ordinary shares sold	5,917,160
Ordinary shares, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Purchase price (in dollars per share)	$ 42.25
Gross proceeds from issuance	$ 250,000	$ 248,406
Offering expenses	$ 1,600

(LOSS) EARNINGS PER SHARE (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Numerator:
Net (loss) income	$ (39,956)	$ (7,762)	$ (60,575)	$ 2,569
Denominator:
Weighted average number of ordinary shares outstanding	145,896	136,106	144,732	134,670
Effect of dilutive securities:
Dilutive ordinary share equivalents (in shares)				8,352
Shares used in calculating diluted earnings (loss) per share	145,896	136,106	144,732	143,022
Stock options
Effect of dilutive securities:
Dilutive ordinary share equivalents (in shares)				6,929
Restricted stock units
Effect of dilutive securities:
Dilutive ordinary share equivalents (in shares)				1,423

(LOSS) EARNINGS PER SHARE (Details 2) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Mar. 31, 2013	Sep. 30, 2014	Sep. 30, 2013
Denominator:
Anti-dilutive potential common equivalent shares excluded from calculation of net (loss) income per share	11,404	10,470	11,426	1,084
Stock options
Denominator:
Anti-dilutive potential common equivalent shares excluded from calculation of net (loss) income per share	9,721	9,241	9,605	1,084
Restricted stock units
Denominator:
Anti-dilutive potential common equivalent shares excluded from calculation of net (loss) income per share	1,683	1,229	1,821

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
INCOME TAXES (Details) - USD ($) $ in Thousands	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
INCOME TAXES
Income tax provision (benefit)	$ 3,523	$ 233	$ 5,766	$ 7,818
Discrete benefit from the settlement of uncertain tax benefits		$ 3,000		$ 3,000